AI Terminal
Xbrane Biopharma
Board/Management Information • Dec 16, 2020
3128_rns_2020-12-16_d4af27b5-ea6d-4b00-81d2-61066336a67f.pdf
Board/Management Information
Open in ViewerOpens in native device viewer
Nina Ivers joins Xbrane Biopharma as Head of HR
Xbrane Biopharma AB (publ) ("Xbrane" or "the company") announces that Nina Ivers has assumed the position as Head of HR and will be part of the management team.
Nina has extensive experience from different HR and business roles in life science companies like Astra, Johnson & Johnson, and Swedish Orphan Biovitrum. She has contributed and worked broadly with Human Resources with strong focus on development of teams and individuals, always driven by business needs.
"I want to welcome Nina to Xbrane. She will be crucial for our continued growth and strive towards being the best place to work across life science companies in Sweden.", says Martin Åmark, CEO.
Contacts
Martin Åmark, CEO/ IR M: +46 (0) 763-093 777 E: [email protected]
About Us
Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.